Omeros' performance has consistently failed to meet expectations, raising concerns about its future prospects. Read more to ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight with its pivotal cardiomyopathy disorder trial. | The FDA has freed Rocket ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles (herpes zoster, or HZ) after a COVID-19 infection. The study was conducted ...

Omeros Corporation (NASDAQ: OMER) Q2 2025 Earnings Call Transcript August 14, 2025 Omeros Corporation beats earnings ...

Objectives To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed the questions for the ...

Original research: Association of renal cortical thickness and renal function in patients with malignant hypertension with thrombotic microangiopathy: a biopsy-based cohort study from China (16 August ...